An updated cost-effectiveness analysis of pazopanib versus sunitinib as first-line treatment for locally advanced or metastatic renal cell carcinoma in Italy

Overview of attention for article published in Journal of Medical Economics, November 2020

Altmetric Badge

Mentioned by

twitter: 1 X user

Readers on

mendeley: 30 Mendeley

So far, Altmetric has seen 1 X post from an account with 1,393 followers.

An updated cost-effectiveness analysis of pazopanib versus sunitinib as first-line treatment for locally advanced or metastatic renal cell carcinoma in Italy https://t.co/lhoBCPNu59

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.